Pharma BD Deal Intelligence

Sanofi SA / Origimm Biotechnology GmbH

2021 · Acquisition/Merger · $170M · Complete

Outcome grade pending — assessed 5 years post-close.

Full analysis, sources & comparables →

The coverage arc

Oct 02, 2018 Almirall Press Release (Seysara/sarecycline) Bullish

Almirall announced today that the U.S. Food and Drug Administration has approved Seysara (sarecycline), a novel, narrow-spectrum tetracycline-derived oral…

Dec 02, 2021 pharmaphorum Bullish

Sanofi has acquired Austrian biotech Origimm to gain a vaccine candidate that the firms believe could be the first preventive immunotherapy for acne. The lead…

Apr 05, 2024 ClinicalTrials.gov NCT06316297 Bullish

Phase 1/2 randomized, placebo-controlled, multi-arm dose-finding study of an acne mRNA vaccine candidate in adults 18-45 with moderate to severe acne. Sponsor…

Source summaries from our enrichment pipeline; follow links for originals.

All 15 sources with sentiment breakdown →

Sanofi acquired Austrian biotech Origimm Biotechnology GmbH (Vienna; seller Sanja Selak) for up to EUR 150 million (EUR 55M upfront plus up to EUR 95M in development and regulatory milestones); the deal completed on Dec 3, 2021. The acquisition added ORI-001 (later ORI-A-ce001 / ORG101), a recombinant-protein therapeutic vaccine targeting Cutibacterium acnes surface antigens, advanced alongside Sanofi's mRNA Center of Excellence. The lead Phase 1 safety/immunogenicity study (NCT05131373, 38 participants) completed in Nov 2023, and Sanofi has since advanced a next-generation acne mRNA vaccine into a Phase 1/2 dose-finding trial (NCT06316297, recruiting from Apr 2024; estimated completion 2028) - the first major industrial commitment to a preventive acne vaccine.

Key facts

Related deals — scored

DealYearValueOutcome
Sanofi SA / Origimm Biotechnology GmbH (this deal)2021$170M
Sanofi SA / Regeneron Pharmaceuticals, Inc.2007$1.0B97
Sanofi SA / Synthelabo S.A.1998$11.0B84
Sanofi SA / Genzyme Corporation2011$20.1B84
Sanofi SA / Amunix Pharmaceuticals Inc.2021$1.2B76
Sanofi SA / Genzyme Corporation2010$18.5B75
Sanofi SA / Translate Bio Inc.2018$805M73

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →